Loading...
•
Mar 31
Gossamer Bio Q1 2025 Earnings Report
Gossamer Bio reported a narrowed net loss and recorded $9.9 million in collaboration revenue in Q1 2025.
Key Takeaways
In Q1 2025, Gossamer Bio reported $9.9 million in collaboration revenue and a net loss of $36.6 million, while continuing to advance its registrational studies for seralutinib. The company closed new patient screening for its Phase 3 PROSERA Study and maintains a strong cash position to fund operations into the first half of 2027.
Reported $9.9 million in collaboration revenue, including $6.6 million from cost reimbursements.
Net loss decreased to $36.6 million from $41.9 million in Q1 2024.
Cash and marketable securities totaled $257.9 million, expected to fund operations into H1 2027.
Patient screening closed for Phase 3 PROSERA Study; topline data expected in February 2026.
Gossamer Bio
Gossamer Bio
Gossamer Bio Revenue by Segment
Revenue by Segment
Contracts with Collaborators Revenue
CapyFin.com Forward Guidance
Gossamer expects to complete enrollment in the Phase 3 PROSERA Study in June 2025 and initiate the SERANATA Study in Q4 2025, while maintaining sufficient funding into the first half of 2027.
Positive Outlook
- PROSERA Phase 3 patient screening closed; full enrollment expected in June 2025.
- Topline data from PROSERA Phase 3 study anticipated in February 2026.
- SERANATA Phase 3 study site activations planned for Q4 2025.
- Collaboration with Chiesi advancing seralutinib development globally.
- Sufficient cash runway projected through H1 2027.
Challenges Ahead
- Ongoing operating losses driven by R&D and G&A expenses.
- Total liabilities exceed total assets by $6.25 million.
- Accumulated deficit surpassed $1.3 billion.
- Continued reliance on successful outcomes from seralutinib trials.
- Potential regulatory and trial execution risks remain for both PROSERA and SERANATA studies.